Article

Toric contact lens recall continues

CooperVision is continuing to work with the FDA, distributors, customers, eye-care practitioners, and contact lens wearers to complete a worldwide recall on certain lots of a contact lens (Avaira Toric, CooperVision) that was begun Aug. 19.

Pleasanton, CA-CooperVision is continuing to work with the FDA, distributors, customers, eye-care practitioners, and contact lens wearers to complete a worldwide recall on certain lots of a contact lens (Avaira Toric, CooperVision) that was begun Aug. 19.

“Our first priority is always the health and safety of all CooperVision lens wearers, and as such we responded quickly to complaints from our customers by initiating a voluntary recall,” said Christine Moench, vice president, global regulatory affairs and quality assurance, CooperVision. “We want to ensure that all consumers are aware of this action and know where to go for more information.”

The company began the recall after an unintended residue was found on certain lots of the toric lenses. The residue may cause hazy vision, discomfort, or eye injuries requiring medical treatment. Not everyone has experienced the same symptoms.

So far, the recall has affected about 600,000 contact lenses in the United States, according to the company. Since the recall began, the company has received some additional complaints of severe eye pain.

Anyone wearing the contact lenses and experiencing symptoms should stop wearing them immediately and contact an eye-care practitioner for advice, according to the company. Those not experiencing symptoms should visit the CooperVision recall Web page, www.coopervision.com/recall, and enter the lot number of the lens package to determine whether the lenses have been recalled, or they can call the company’s toll-free consumer hotline, 855/526-6737.

Those whose lenses have been recalled should immediately remove the lenses, discontinue wearing them, and return the lenses to an eye-care practitioner or the point of purchase.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.